Table 3.

Outcomes of various induction regimens in blastic plasmacytoid dendritic cell neoplasm

Reference	N	Chemo regimen	CR (%)	Relapsea (%)	Median overall survival (months)
Feuillard et al9	5	ALL	80	50	12
	6	AML	100	100	14.5
	10	Lymphoma	80	75	11
Dalle et al39	5	ALL	80	nr	16
	10	AML	40	nr	19
	20	Lymphoma	50	nr	11.5
Tsagarakis et al40	9	ALL	100	33.3	nr
	6	AML	50	33.3	nr
	4	Lymphoma	75	66.7	nr
Dietrich et al41	3	ALL	100	66.7	23
	2	AML	50	100	19
	1	Lymphoma	100	100	6
Lucioni et al29	9	ALL	78	29	12
	4	Lymphoma	50	100	27.5
Hashikawa et al42	2	ALL	100	nr	NR
	4	AML	25	nr	5.5
	11	Lymphoma	73	nr	11
Pagano et al14	15	ALL/lymphoma	67	60	12.3
	26	AML	27	0	7.1
An et al43	3	ALL	67	0	15.1
	1	AML	0	NA
	2	Lymphoma	50	0
Kim et al44	4	Hyper-CVAD	50	100	17
	2	ALL-like	100	100
Martín- Martín et al38	7	ALL	100	43	NR
	9	AML	100	78	11
	9	Lymphoma	78	100	10

Notes: Lymphoma (CHOP/CHOP-like).

^a% relapse out of those achieving a CR with induction. Some studies include patients who received HSCT in consolidation or in first relapse.

Abbreviations: nr, not reported; NR, not reached; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CR, complete remission; NA, not applicable; HSCT, hematopoietic stem cell transplantation.